These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 36249043)
1. Reliability of gradient-based segmentation for measuring metabolic parameters influenced by uptake time on 18F-PSMA-1007 PET/CT for prostate cancer. Lau YC; Chen S; Ho CL; Cai J Front Oncol; 2022; 12():897700. PubMed ID: 36249043 [TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
3. Optimization of PET reconstruction algorithm, SUV thresholding algorithm and PET acquisition time in clinical 11C-acetate PET/CT. Strandberg S; Hashemi A; Axelsson J; Riklund K PLoS One; 2018; 13(12):e0209169. PubMed ID: 30543705 [TBL] [Abstract][Full Text] [Related]
4. Intra-Individual Comparison of 18F-PSMA-1007 and 18F-FDG PET/CT in the Evaluation of Patients With Prostate Cancer. Zhou X; Li Y; Jiang X; Wang X; Chen S; Shen T; You J; Lu H; Liao H; Li Z; Cheng Z Front Oncol; 2020; 10():585213. PubMed ID: 33604285 [TBL] [Abstract][Full Text] [Related]
5. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731 [TBL] [Abstract][Full Text] [Related]
6. Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747 [TBL] [Abstract][Full Text] [Related]
7. Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CT. Mihatsch PW; Beissert M; Pomper MG; Bley TA; Seitz AK; Kübler H; Buck AK; Rowe SP; Serfling SE; Hartrampf PE; Werner RA Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053434 [TBL] [Abstract][Full Text] [Related]
8. Significance of metabolic tumor volume and total lesion uptake measured using Ga-68 labelled prostate-specific membrane antigen PET/CT in primary staging of prostate cancer. Kubilay E; Akpinar Ç; Oǧuz ES; Araz MS; Soydal Ç; Baltacı S; Ürün Y; Süer E Urol Oncol; 2022 Sep; 40(9):408.e19-408.e25. PubMed ID: 35902300 [TBL] [Abstract][Full Text] [Related]
9. Quantitative evaluation of PSMA PET imaging using a realistic anthropomorphic phantom and shell-less radioactive epoxy lesions. Fedrigo R; Kadrmas DJ; Edem PE; Fougner L; Klyuzhin IS; Petric MP; Bénard F; Rahmim A; Uribe C EJNMMI Phys; 2022 Jan; 9(1):2. PubMed ID: 35032234 [TBL] [Abstract][Full Text] [Related]
11. High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with Werner RA; Habacha B; Lütje S; Bundschuh L; Higuchi T; Hartrampf P; Serfling SE; Derlin T; Lapa C; Buck AK; Essler M; Pienta KJ; Eisenberger MA; Markowski MC; Shinehouse L; AbdAllah R; Salavati A; Lodge MA; Pomper MG; Gorin MA; Bundschuh RA; Rowe SP Mol Imaging; 2022; 2022():7056983. PubMed ID: 35283693 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of early imaging with Özülker F Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(2):100-105. PubMed ID: 30514659 [TBL] [Abstract][Full Text] [Related]
14. Schmidkonz C; Cordes M; Schmidt D; Bäuerle T; Goetz TI; Beck M; Prante O; Cavallaro A; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1862-1872. PubMed ID: 29725716 [TBL] [Abstract][Full Text] [Related]
15. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT. Baumann R; Koncz M; Luetzen U; Krause F; Dunst J Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556 [TBL] [Abstract][Full Text] [Related]
16. Comparison of [ Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246 [TBL] [Abstract][Full Text] [Related]
17. qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using Gafita A; Bieth M; Krönke M; Tetteh G; Navarro F; Wang H; Günther E; Menze B; Weber WA; Eiber M J Nucl Med; 2019 Sep; 60(9):1277-1283. PubMed ID: 30850484 [TBL] [Abstract][Full Text] [Related]
18. Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma. Sahlmann CO; Meller B; Bouter C; Ritter CO; Ströbel P; Lotz J; Trojan L; Meller J; Hijazi S Eur J Nucl Med Mol Imaging; 2016 May; 43(5):898-905. PubMed ID: 26563122 [TBL] [Abstract][Full Text] [Related]
19. Repeatability of quantitative parameters of 18F-fluoride PET/CT and biochemical tumour and specific bone remodelling markers in prostate cancer bone metastases. Wassberg C; Lubberink M; Sörensen J; Johansson S EJNMMI Res; 2017 Dec; 7(1):42. PubMed ID: 28508284 [TBL] [Abstract][Full Text] [Related]